Ronald T. Nixon

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

The Catalyst Group specializes in providing value-added mezzanine and equity capital to middle-market companies in the manufacturing, distribution and service sectors. They do not invest in real estate, oil and gas E&P or financial services. The firm looks for profitable, growth-oriented companies with revenues of $10 million to $100 million and stable operating margins. Companies must have been in operation for at least 3 years and should have a solid, defensible business franchise and a defined requirement for capital. The Catalyst Group participates in growth capital and expansion financings, acquisitions, recapitalizations, generational changes of ownership and MBOs of private companies or divisions of larger companies. They invest only in US companies with a preference for companies in the Southwest.The firm makes equity investments of $2 million to $10 million. They may take majority or minority ownership positions. The Catalyst Group prefers to conservatively capitalize their portfolio companies to meet future growth expectations. They make mezzanine investments of $1 million to $7 million. These investments are structured as subordinated debt with warrants or other yield-enhancing mechanisms.

Catalyst/Hall Growth Capital invests in manufacturing, distribution and service companies with solid, defensible business franchises and a defined requirement for capital. They provide value-added mezzanine and equity capital for middle-market companies including: capital for growth and expansion, recapitalization of family owned or closely held companies, generational changes in ownership and MBOs of private companies or divisions of larger companies